GlassScriptPhysician profile
Kayla L Epstein
NPI 1477028991
$2,521.23
in general payments reported to CMS, 2019-2025
9 companies · $472 in 2025
The $472 reported for 2025 was more than what 79% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $421 · 2023: $774 · 2024: $653 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $766.66 | 2022-2024 | Cerepak Uniform, Embotrap, Emboguard |
| Integra Lifesciences Corporation | $649.77 | 2024-2025 | Codman Hakim, Cusa Clarity, Codman Certas |
| Stryker Corporation | $446.91 | 2021-2023 | Target, Trevo |
| Microvention, INC. | $190.47 | 2022-2023 | Web Aneurysm Embolization System |
| Abbvie INC. | $135.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $113.41 | 2021 | |
| Microtransponder, INC. | $90.83 | 2024 | |
| Medtronic, INC. | $88.23 | 2022-2024 | Pipeline, Solitaire X |
| Asahi Intecc USA, INC. | $39.95 | 2024 | Peripheral Vascular |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.